非注射胰島素市場預測－按產品、劑量、通路和地區分類的全球分析－至2034年

全球非注射胰島素市場預計到 2026 年將達到 21 億美元，並在預測期內以 15.2% 的複合年成長率成長，到 2034 年將達到 66 億美元。

非注射型胰島素是指無需經由針頭注射到皮膚內，可經由其他途徑給藥的胰島素。這些給藥途徑包括局部貼片、吸入、口服或鼻噴霧。非注射型胰島素的出現為需要胰島素治療的患者提供了更方便的選擇，有望提高治療依從性，並整體改善患者的整體生活品質。

據 Biocon 公司稱，該公司於 2022 年 6 月完成了其口服胰島素「Tregopil」治療 1 型糖尿病的 1 期臨床試驗，但目前正在繼續進行其治療 2 型糖尿病的 3 期臨床試驗。

藥物傳輸技術的進步

藥物輸送技術的持續進步是市場成長的主要驅動力。這些創新技術正在改變糖尿病管理領域，使非注射胰島素替代品更加可靠、高效，並受到患者和醫療專業人員的青睞。此外，這些發展也提高了胰島素劑量的準確性和一致性，從而增強了非注射胰島素裝置的整體療效。

副作用

與其他藥物一樣，非注射胰島素也會產生副作用。吸入式胰島素可能引起咳嗽和喉嚨刺激。口服胰島素可能與消化酵素產生交互作用或引起胃腸道問題。患者不願意接受非注射胰島素療法是市場成長的主要障礙。儘管非注射胰島素療法具有明顯的優勢和便捷的使用方式，但有些人仍然不願意放棄熟悉的注射方式。

糖尿病患者數量增加

隨著糖尿病在全球日益普遍，非注射胰島素給藥系統正逐漸受到歡迎。對於那些不願意或難以接受注射的糖尿病患者來說，非注射胰島素方案無疑是個極具吸引力的選擇。此外，提高病患、醫護人員和民眾對非注射胰島素方案的認知度和益處，也推動了此類方案的普及和市場成長。

高成本

如果核准，非注射胰島素的價格可能高於傳統注射胰島素。研發和給藥系統的進步可能會推高成本。然而，監管機構在非注射胰島素的研發和核准中面臨許多挑戰。確保其在一般使用中的安全性和有效性通常需要嚴格的監管審查和長期的臨床試驗。這些因素阻礙了市場擴張。

新冠疫情的感染疾病：

新冠疫情對非注射胰島素市場產生了多方面的影響。儘管初期供應鏈中斷，醫療機構進入也受到限制，但對創新型糖尿病治療方案的需求依然強勁。隨著患者尋求減少就醫次數的替代方案，非注射胰島素的需求進一步成長。此外，疫情加速了遠端醫療的普及，使患者更容易與醫療專業人員討論這些治療方案。

在預測期內，噴灑領域預計將成為最大的領域。

由於噴霧劑使用方便，預計在預測期內，噴霧劑市場規模將佔據最大佔有率。對於希望以更簡單、更舒適的方式管理糖尿病的患者而言，吸入式胰島素噴霧劑被認為是一種極具吸引力且侵入性較小的注射替代方案。此外，藥物傳輸技術的顯著進步確保了這些噴霧劑的精準高效給藥。

在預測期內，醫院藥房細分市場預計將呈現最高的複合年成長率。

在預測期內，醫院藥房領域預計將呈現最高的複合年成長率。醫療機構在糖尿病的管理和治療中發揮著至關重要的作用，也是非注射胰島素產品的主要供應中心。醫院的臨床環境增強了病人對非注射胰島素替代品的信心。這些因素綜合起來意味著，醫院藥局推廣和供應非注射胰島素溶液將使眾多患者受益。

市佔率最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。其主導地位歸功於該地區糖尿病患病率高、醫療保健基礎設施完善以及對研發和創新的高度重視。尤其值得注意的是，患者對非注射胰島素替代方案的認知度和接受度很高。對便利、以患者為中心的糖尿病治療方案的高需求正在鞏固該地區的顯著市場佔有率。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。該地區糖尿病高發生率、都市化迅速以及醫療基礎設施不斷完善，推動了對創新糖尿病管理解決方案的需求成長。政府措施以及與製藥公司的合作進一步促進了市場成長。基於這些原因，亞太地區憑藉龐大且多元化的患者群體和前景廣闊的醫療保健項目，已成為市場的重要參與者。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

• 企業概況
  • 對其他市場參與者（最多 3 家公司）進行全面分析
  • 對主要公司進行SWOT分析（最多3家公司）
• 區域細分
  • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
• 競爭性標竿分析
  • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

• 概括
• 相關利益者
• 調查範圍
• 調查方法
• 研究材料

第3章 市場趨勢分析

• 促進因素
• 抑制因子
• 機會
• 威脅
• 產品分析
• 新興市場
• 新冠疫情的感染疾病

第4章：波特五力分析

• 供應商的議價能力
• 買方的議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的競爭

第5章 全球非注射型胰島素市場：依產品分類

• 口服
• 經皮吸收
• 鼻腔
• 舌下
• 其他產品

第6章：全球非注射胰島素市場：依劑量分類

• 藥片
• 噴

第7章：全球非注射胰島素市場：依通路分類

• 醫院藥房
• 網路商店
• 藥局

第8章 全球非注射胰島素市場：按地區分類

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太國家
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美國家
• 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 卡達
  • 南非
  • 其他中東和非洲國家

第9章 主要發展

• 合約、夥伴關係、合作關係、合資企業
• 收購與併購
• 新產品發布
• 業務拓展
• 其他關鍵策略

第10章：公司簡介

• Generex Biotechnology Corp.
• Biodel, Inc.
• Oramed Pharmaceuticals, Inc.
• Diasome Pharmaceuticals, Inc.
• Midatech Pharma Plc
• Shreya Life Sciences Pvt. Ltd.
• Boston Therapeutics, Inc.
• Diabetology Ltd.
• Emisphere Technologies, Inc.
• Coromed, Inc.
• Novo Nordisk
• Sanofi
• Eli Lilly
• MannKind Corporation
• Adocia
• Oramed Pharmaceuticals
• Dance Biopharm
• Biocon
• Janssen Pharmaceuticals

According to Stratistics MRC, the Global Non-Injectable Insulin Market is accounted for $2.1 billion in 2026 and is expected to reach $6.6 billion by 2034 growing at a CAGR of 15.2% during the forecast period. Non-injectable insulin refers to forms of insulin that do not require injection through a needle into the skin but instead can be administered through alternative methods. These techniques can be applied topically as patches or through inhalation, oral medication, or nasal sprays. With the introduction of non-injectable insulin, people who need insulin therapy will have more convenient options, which could lead to better treatment adherence and an overall improvement in quality of life.

According to Biocon, it terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus

Market Dynamics:

Driver:

Technological developments in medicine delivery

The continuous progress in medication delivery technology is a major driver of the market's growth. The field of diabetes management is changing as a result of these innovative technical advancements, which make non-injectable insulin substitutes more dependable, efficient, and appealing to patients and medical professionals alike. Furthermore, these developments have improved insulin dose accuracy and consistency, increasing the overall effectiveness of non-injectable insulin devices.

Restraint:

Side effects

Like any medication, non-injectable insulin can have side effects. Inhaled insulin might cause coughing or throat irritation. Oral insulin might interact with digestive enzymes or cause gastrointestinal issues. The reluctance of patients to embrace non-injectable insulin techniques presents a significant obstacle to the market's growth. Even with the obvious benefits and ease of use of non-injectable insulin alternatives, some people are reluctant to abandon the comfortable and well-recognized method of insulin injections.

Opportunity:

Rising diabetes prevalence

Alternative insulin administration systems are becoming more and more popular as diabetes becomes more commonplace worldwide. Non-injectable alternatives present a compelling substitute for diabetes individuals who may be uncomfortable with or struggle with injections. Increased adoption and market expansion are also facilitated by initiatives to inform patients, medical professionals, and the general public about the availability and advantages of non-injectable insulin solutions.

Threat:

High cost

If approved, non-injectable insulin may cost more than conventional injectable insulin. Expenses may rise as a result of R&D and technological advancements in delivery systems. Regulators have encountered difficulties with the development and approval of non-injectable insulin, though. Regulatory scrutiny and lengthy clinical trials are frequently necessary to ensure safety and efficacy for general use. The market's expansion is being hindered by these factors.

Covid-19 Impact:

The market for non-injectable insulin has been affected by the COVID-19 pandemic in a variety of ways. The initial interruption of the supply chain and limited accessibility to healthcare facilities notwithstanding, there was an increasing demand for creative solutions to treat diabetes. There was an increase in demand for non-injectable insulin options as patients looked for alternatives to lessen their hospital visits. In addition, the epidemic hastened the use of telemedicine, facilitating patient access to and discussion of these choices with medical professionals.

The sprays segment is expected to be the largest during the forecast period

The sprays segment is expected to be the largest during the forecast period due to its convenience and patient-friendly attributes. Patients looking for simpler and less unpleasant ways to manage their diabetes may find inhalable insulin sprays appealing as a less intrusive substitute for injections. Furthermore, these sprays guarantee accurate and efficient dosage due to notable developments in drug delivery technology.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Healthcare facilities play a pivotal role in the management and treatment of diabetes, rendering them notable hubs for the delivery of insulin products that are not injectable. Trust in non-injectable insulin alternatives is fostered by the clinical context of hospitals. A broad patient population can benefit from the promotion and provision of non-injectable insulin solutions by hospital pharmacy due to the confluence of these variables.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. High diabetes prevalence, a robust healthcare infrastructure, and a strong emphasis on research and innovation in the region contribute to its prominence. Notable are the patient's awareness and readiness to switch to non-injectable insulin substitutes. The region's significant market share is cemented by the high need for accessible and patient-focused diabetes treatment solutions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region's high diabetes prevalence, rapid urbanization, and expanding healthcare infrastructure have contributed to increased demand for innovative diabetes management solutions. Initiatives from the government and partnerships with pharmaceutical firms have further encouraged market expansion. Because of this, it is positioned as a significant player in the market thanks to its large and diverse patient population and encouraging healthcare programs.

Key players in the market

Some of the key players in Non-Injectable Insulin market include Generex Biotechnology Corp., Biodel, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Midatech Pharma Plc, Shreya Life Sciences Pvt. Ltd., Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Coromed, Inc., Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Adocia, Oramed Pharmaceuticals, Dance Biopharm, Biocon and Janssen Pharmaceuticals.

Key Developments:

In November 2023, Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

In February 2022, Biocon made a significant move by acquiring Viatris' biosimilar portfolio for a substantial sum of USD 3.335 billion. This strategic acquisition bolstered Biocon's biosimilar product offerings and had a positive impact on the company's revenue generation.

Products Covered:

• Oral
• Transdermal
• Nasal
• Sublingual
• Other Products

Dosages Covered:

• Pills
• Sprays

Distribution Channels Covered:

• Hospital Pharmacies
• Online Stores
• Drug Stores

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Non-Injectable Insulin Market, By Product

• 5.1 Introduction
• 5.2 Oral
• 5.3 Transdermal
• 5.4 Nasal
• 5.5 Sublingual
• 5.6 Other Products

6 Global Non-Injectable Insulin Market, By Dosage

• 6.1 Introduction
• 6.2 Pills
• 6.3 Sprays

7 Global Non-Injectable Insulin Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Stores
• 7.4 Drug Stores

8 Global Non-Injectable Insulin Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Generex Biotechnology Corp.
• 10.2 Biodel, Inc.
• 10.3 Oramed Pharmaceuticals, Inc.
• 10.4 Diasome Pharmaceuticals, Inc.
• 10.5 Midatech Pharma Plc
• 10.6 Shreya Life Sciences Pvt. Ltd.
• 10.7 Boston Therapeutics, Inc.
• 10.8 Diabetology Ltd.
• 10.9 Emisphere Technologies, Inc.
• 10.10 Coromed, Inc.
• 10.11 Novo Nordisk
• 10.12 Sanofi
• 10.13 Eli Lilly
• 10.14 MannKind Corporation
• 10.15 Adocia
• 10.16 Oramed Pharmaceuticals
• 10.17 Dance Biopharm
• 10.18 Biocon
• 10.19 Janssen Pharmaceuticals

List of Tables

• Table 1 Global Non-Injectable Insulin Market Outlook, By Region (2023-2034) ($MN)
• Table 2 Global Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 3 Global Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 4 Global Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 5 Global Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 6 Global Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 7 Global Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 8 Global Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 9 Global Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 10 Global Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 11 Global Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 12 Global Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 13 Global Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 14 Global Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)
• Table 15 North America Non-Injectable Insulin Market Outlook, By Country (2023-2034) ($MN)
• Table 16 North America Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 17 North America Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 18 North America Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 19 North America Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 20 North America Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 21 North America Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 22 North America Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 23 North America Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 24 North America Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 25 North America Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 26 North America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 27 North America Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 28 North America Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)
• Table 29 Europe Non-Injectable Insulin Market Outlook, By Country (2023-2034) ($MN)
• Table 30 Europe Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 31 Europe Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 32 Europe Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 33 Europe Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 34 Europe Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 35 Europe Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 36 Europe Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 37 Europe Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 38 Europe Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 39 Europe Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 40 Europe Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 41 Europe Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 42 Europe Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)
• Table 43 Asia Pacific Non-Injectable Insulin Market Outlook, By Country (2023-2034) ($MN)
• Table 44 Asia Pacific Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 45 Asia Pacific Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 46 Asia Pacific Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 47 Asia Pacific Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 48 Asia Pacific Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 49 Asia Pacific Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 50 Asia Pacific Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 51 Asia Pacific Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 52 Asia Pacific Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 53 Asia Pacific Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 54 Asia Pacific Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 55 Asia Pacific Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 56 Asia Pacific Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)
• Table 57 South America Non-Injectable Insulin Market Outlook, By Country (2023-2034) ($MN)
• Table 58 South America Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 59 South America Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 60 South America Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 61 South America Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 62 South America Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 63 South America Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 64 South America Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 65 South America Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 66 South America Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 67 South America Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 68 South America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 69 South America Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 70 South America Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)
• Table 71 Middle East & Africa Non-Injectable Insulin Market Outlook, By Country (2023-2034) ($MN)
• Table 72 Middle East & Africa Non-Injectable Insulin Market Outlook, By Product (2023-2034) ($MN)
• Table 73 Middle East & Africa Non-Injectable Insulin Market Outlook, By Oral (2023-2034) ($MN)
• Table 74 Middle East & Africa Non-Injectable Insulin Market Outlook, By Transdermal (2023-2034) ($MN)
• Table 75 Middle East & Africa Non-Injectable Insulin Market Outlook, By Nasal (2023-2034) ($MN)
• Table 76 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sublingual (2023-2034) ($MN)
• Table 77 Middle East & Africa Non-Injectable Insulin Market Outlook, By Other Products (2023-2034) ($MN)
• Table 78 Middle East & Africa Non-Injectable Insulin Market Outlook, By Dosage (2023-2034) ($MN)
• Table 79 Middle East & Africa Non-Injectable Insulin Market Outlook, By Pills (2023-2034) ($MN)
• Table 80 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sprays (2023-2034) ($MN)
• Table 81 Middle East & Africa Non-Injectable Insulin Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 82 Middle East & Africa Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
• Table 83 Middle East & Africa Non-Injectable Insulin Market Outlook, By Online Stores (2023-2034) ($MN)
• Table 84 Middle East & Africa Non-Injectable Insulin Market Outlook, By Drug Stores (2023-2034) ($MN)